Neurotrophic Keratopathy Clinical Trial
Official title:
In Vivo Evaluation of Corneal Nerves and Epithelial Healing After Treatment With Nerve Growth Factor for Neurotrophic Keratopathy
A prospective, longitudinal, cross-sectional, observational Study with a 8-week Follow-up to evaluate the renewal of corneal nerves structure and function in patients with Neurotrophic Keratopathy treated with recombinant human Nerve Growth Factor (rhNGF) eyedrops.
This Study shows that topical treatment with Recombinant Nerve Growth Factor (rhNGF) improved corneal sensitivity and increased sub-basal nerves density, promoting corneal healing of persistent epithelial defects and corneal ulcers in patients with stage 2 and 3 NK ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02600429 -
Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
|
Phase 3 | |
| Recruiting |
NCT04604834 -
Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy
|
N/A | |
| Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
| Completed |
NCT04957758 -
Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
|
Phase 2 | |
| Terminated |
NCT03084861 -
A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT06411145 -
Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis
|
Phase 4 | |
| Recruiting |
NCT05555589 -
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
|
Phase 3 | |
| Not yet recruiting |
NCT06331910 -
Efficacy and Safety of Topical Insulin for Neurotrophic Corneal Ulcers
|
Phase 4 |